Results of a randomized multinational study comparing the outcomes of kidney transplant patients undergoing induction therapy with Thymoglobulin® (Anti-thymocyte globulin [Rabbit]) with those receiving induction therapy with basiliximab have recently been published at the New England Journal of Medicine. 
…Rabbit Antithymocyte Globulin versus Basiliximab for Induction in Renal Transplantation, showed that treatment with Thymoglobulin resulted in a significantly reduced risk of acute rejection and acute rejection requiring antibody therapy, and a similar risk of delayed graft function, graft loss and death.
The study, which involved 278 patients at high risk for acute rejection or delayed graft function following a kidney transplant from a deceased donor, wanted a composite measure of the first occurrence of four factors: acute rejection, delayed graft function, graft loss and death.
A product of Genzyme Corporation (Nasdaq: GENZ), Thymoglobulin® is an immunosuppressive product that contains cytotoxic antibodies directed against antigens expressed on human T-lymphocytes.
Find more details from the press release.
.jpg)
Comment Preview